Mesoblast Limited (ASX: MSB)

Market Cap	1.69B
Revenue (ttm)	8.85M
Net Income (ttm)	-131.83M
Shares Out	1.14B
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,697,277
Open	1.580
Previous Close	1.575
Day's Range	1.470 - 1.585
52-Week Range	0.255 - 1.830
Beta	2.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 18, 2024

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.

Financial numbers in USD